is Developing 3D-bioprinted Implants

is Developing 3D-bioprinted Implants

Regeneration of Breast Tissue

August 5, 2019, CollPlant (NASDAQ:CLGN) (the "Company"), a regenerative medicine company, announced today that

it is developing 3D bioprinted implants for regeneration of breast tissue and has successfully produced first prototypes. The implants

will be comprised of CollPlant's proprietary type I recombinant human collagen and additional materials. Loaded with fat

cells taken from the patient, these implants are intended to promote breast tissue regeneration. Eventually, the scaffold is designed

to degrade and be replaced by newly grown natural breast tissue, that is free of any foreign material.

"The implants we are

developing leverage our 3D bioprinting technology and the unique properties of our recombinant human collagen, that has an excellent

safety profile. We believe that our technology can eliminate the high risk for adverse events associated with permanent breast

implants and provide a revolutionary alternative. This technology is already raising interest from leading companies in this segment,"

stated CollPlant CEO, Yehiel Tal.

CollPlant is a regenerative

medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Our products are based on our rhCollagen

(recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications

for the diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen

BioInk product line is ideal for 3D bioprinting of tissues and organs. Last year we entered into a licensing agreement with United

Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant

For more information about CollPlant,

visit http://www.collplant.com

Safe Harbor Statements

This press release may include

forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's

objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments

that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often

characterized by terminology such as "believes," "hopes," "may," "anticipates,"

"should," "intends," "plans," "will," "expects," "estimates,"

"projects," "positioned," "strategy" and similar expressions and are based on assumptions and

assessments made in light of management's experience and perception of historical trends, current conditions, expected future

developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance

and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied

in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities

and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history

of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to

obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing

clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk, dermal fillers for aesthetics,

VergenixSTR, and VergenixFG; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory

action with respect to rhCollagen based BioInk, dermal fillers for aesthetics, VergenixSTR, and VergenixFG including but not limited

to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope

of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based BioInk,

dermal fillers for aesthetics, VergenixSTR, and VergenixFG; the Company's ability to establish sales and marketing capabilities

or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability

to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties

to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain

for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property

rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political,

and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in

the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties

affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual

report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The

forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's

current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update

or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact at CollPlant:

Tel: + 972-73-2325600- 0

Email: Eran@collplant.com